Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?
PAGD's intention to improve profitability at the expense of revenue scale is obvious. Switching from 2C to 2B model is a double-edged sword. Whether the transformation is successful remains to be seen
Equity Bottom-Up
303 Views, 15 Mar 2023 08:55
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- Unlimited Research Summaries
- Personalised Alerts
- Custom Watchlists
- Company Analytics & News
- Events & Webinars
Trusted by:
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Mar.31) - 8th National VBP Result, Chinese Patent Medicine VBP, AIM Vaccine02 Apr 2023
- China Traditional Chinese Medicine (TCM) Industry - TCM Is Becoming Indispensable in the Portfolio30 Mar 2023
- Sipai Health Technology (314.HK) - Unjustified Valuation and Problematic Business Model29 Mar 2023
- Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?15 Mar 2023
- JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation09 Mar 2023
- Keymed Biosciences (2162.HK) - We Have High Hopes for Keymed, but Valuation Is Expensive21 Feb 2023
- Jacobio Pharmaceuticals Placement (1167.HK) - We Keep Hope for Jacobio Because of Dr. Wang Yinxiang13 Feb 2023
- Ping An Healthcare and Technology (1833.HK) - The New Acquisition Is Hard to Turn Things Around01 Nov 2022
- Ping An Healthcare and Technology (1833.HK) - Untenable Business Model Worsen the Logic and Outlook22 Jun 2022
x